Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Visual axis opacity common after IOL implantation in children

16 Sep 2020
Abbott opens us$60 million plant in Kedah

Visual axis opacity (VAO) frequently occurs following intraocular lens (IOL) implantation in early childhood, a recent study has found.

This population-based (UK and Ireland) prospective, inception cohort study was conducted through a national clinical network, including 105 children (n=162 eyes; 57 with bilateral cataract, 48 with unilateral cataract) undergoing primary IOL implantation in the first 2 years of life between January 2009 and December 2010.

The authors also performed an observational longitudinal study with multilevel, multivariable modeling to assess the associations between outcome of interest and child- and treatment-specific factors, including age, axial length, socioeconomic status, IOL model, and postoperative steroid use.

Sixty-seven eyes (45 percent) developed VAO typically within the first postoperative year. Use of a 3-pice IOL model (odds ratio [OR], 0.3, 95 percent confidence interval [CI], 0.09–0.99; p=0.03) and increasing age at surgery (OR, 0.97, 95 percent CI, 0.95–0.99; p=0.02) each showed a protective effect against the development of proliferative VAO.

Moreover, inflammatory VAO independently correlated with socioeconomic deprivation (OR, 5.39, 95 percent CI, 1.46–19.89; p=0.01).

“The findings of this prospective cohort study suggest that the use of 3-piece IOL models may reduce the risk of pseudophakic VAO in children younger than 2 years of age,” the authors said.

“Appropriate correction of aphakia is key to good outcomes. Strategies to target the increased risk of VAO after primary IOL implantation in infancy are necessary,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).